Nasdaq:US$15.16 (+0.08) | HKEX:HK$23.05 (-0.45) | AIM:£2.25 (+0)
Search
Announcements
1234
5
67891011121314151617
found Documents: 833
Announcements & Press Releases, Group | 1 Aug 2022

HUTCHMED Reports 2022 Interim Results and Provides Business Updates
Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-TAGRISSO® NSCLC1 patients with hig
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 1 Aug 2022

HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
Hong Kong, Shanghai & Florham Park, NJ — Monday, August 1, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a bridging study of tazemetostat in China. The first patient receiv
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 15 Jul 2022

HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China
— HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter clinical studies — Hong Kong, Shanghai & Florham Park, NJ — Friday, July 15, 2022: HUTCH
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 13 Jul 2022

HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting
— 49% ORR amongst SAVANNAH patients with higher MET levels — Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 13, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the first presentation of
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 6 Jul 2022

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007
San Diego, Shanghai, Hong Kong and Sydney — Wednesday, July 6, 2022: Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, based in Australi
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 4 Jul 2022

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jun 2022

Total Voting Rights
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Jun 2022

Blocklisting Six Monthly Return
Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, June 29, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:   1. Name of
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 27 Jun 2022

HUTCHMED to Announce 2022 Half-Year Financial Results
Hong Kong, Shanghai & Florham Park, NJ — Monday, June 27, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2022 on Monday, August 1, 2022 at 7:00
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 16 Jun 2022

List of Directors and Their Roles and Functions
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Jun 2022

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 1 Jun 2022

HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, June 1, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that TAZVERIK® (tazemetostat) has been approved by the Health Commission and Medical Pr
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group, Regulatory Notice | 30 May 2022

Notice of Publication of 2021 Sustainability Report
The English and Chinese versions of the 2021 Sustainability Report (the “Sustainability Report”) are available on the website of the Company at www.hutch-med.com and that of Hong Kong Exchanges and Clearing Limited (“HKEx”) at www.hkexnews.hk
Read More
HKEX Notification Letter (PDF)2021 Sustainability Report
Announcements & Press Releases, Regulatory Notice | 24 May 2022

Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, May 24, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on May 23, 2022, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 16 May 2022

List of Directors and Their Roles and Functions
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 16 May 2022

Appointment of Non–Executive Director
Hong Kong, Shanghai & Florham Park, NJ — Monday, May 16, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announces that Mr Lefei Sun has been appointed as a Non-Executive Director with effect from May 16, 2022 an
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Regulatory Notice | 3 May 2022

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 2 May 2022

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
HUTCHMED to hold a conference call at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT   Hong Kong, Shanghai & Florham Park, NJ — Monday, May 2, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) anno
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 27 Apr 2022

Annual General Meeting held on April 27, 2022 – Poll Results
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 27, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and special resolution put to its Annual G
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 21 Apr 2022

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 21, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on A
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 4 Apr 2022

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 31 Mar 2022

Update on Status under Holding Foreign Companies Accountable Act
Hong Kong, Shanghai & Florham Park, NJ — Thursday, March 31, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; SEHK:13) provides an update on its status under the Holding Foreign Companies Accountable Act (th
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Event, Regulatory Notice | 23 Mar 2022

Annual General Meeting 2022
Date: Wednesday, April 27, 2022 Time: 6:00 pm Hong Kong Time (11:00 am London Time) Location: 18th Floor, Hutchison Telecom Tower, 99 Cheung Fai Road, Tsing Yi, Hong Kong  
Read More
2021 Annual ReportCircularNotice of AGM 2022Proxy Form for AGM 2022Notification to New Registered holder and Reply FormNotification to Registered Shhs and Request FormNotification to Non-Registered Shareholders and Request FormOnline AGM User Guide (PDF)Amended and Restated Memorandum and Articles of Association (PDF)
Announcements & Press Releases, Group | 23 Mar 2022

2021 Annual Report and Notice of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, March 23, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that its 2021 Annual Report together with the Notice of Annual General Meeting and the For
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 11 Mar 2022

Update on Status under Holding Foreign Companies Accountable Act
Hong Kong, Shanghai & Florham Park, NJ — Friday, March 11, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; SEHK:13) would like to provide an update on its status under the Holding Foreign Companies Account
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 9 Mar 2022

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 9, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2021 annual results of HUTCHMED on March 3, 2022, the follo
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 7 Mar 2022

HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer
Hong Kong, Shanghai & Florham Park, NJ — Monday, March 7, 2022: (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq:​
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 4 Mar 2022

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
HKEX Announcement
Announcements & Press Releases, Regulatory Notice | 3 Mar 2022

Publication of Form 20-F
HKEX Announcement
Announcements & Press Releases, Group | 3 Mar 2022

HUTCHMED announces retirement of CEO and appointment of new CEO
Hong Kong, Shanghai & Florham Park, NJ – Thursday, March 3, 2022: (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces: the retirement of Mr. Christian Hogg after almost 22 years with the Company, including
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 3 Mar 2022

HUTCHMED Reports 2021 Full Year Results and Provides Business Updates
Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE® growth and the 2021 launches of SULANDA® and ORPATHYS®; Positive SAVANNAH, CALYPSO and VIKTORY studies triggered five registration studies on ORPATHYS® in lung cancer, kidne
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Mar 2022

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 1 Mar 2022

HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau
— First homegrown innovative medicine approved in Macau based on China clinical data — Hong Kong, Shanghai & Florham Park, NJ –– Tuesday, March 1, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today an
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 7 Feb 2022

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 7 Feb 2022

HUTCHMED to Announce 2021 Final Results
Hong Kong, Shanghai & Florham Park, NJ — Monday, February 7, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2021 on Thursday, March 3, 2022 at 7:00
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 4 Feb 2022

HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China
Hong Kong, Shanghai & Florham Park, NJ — Friday, February 4, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase Ib/II study in China of HMPL-453, an investigational novel sele
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 20 Jan 2022

HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China
Hong Kong, Shanghai & Florham Park, NJ –– Thursday, January 20, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, hi
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 19 Jan 2022

HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, January 19, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing international Phase I/Ib trial of fruquintinib will
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 17 Jan 2022

TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 12 Jan 2022

HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia
Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, January 12, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical Products Admin
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 10 Jan 2022

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China
— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED — — HMPL-760 is HUTCHMED’s fifth candidate in clinical development for hematological malignancies, including amdizalisib and HMPL-523 t
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 4 Jan 2022

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Dec 2021

Blocklisting Six Monthly Return
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Dec 2021

Total Voting Rights
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Group | 20 Dec 2021

HUTCHMED Included in FTSE Russell Indexes
Hong Kong, Shanghai & Florham Park, NJ — Monday, December 20, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has been included by FTSE Russell in the FTSE Global Equity Index Series (“GEIS”
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 15 Dec 2021

Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, December 15, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on December 14, 2021, it granted share options under the Share Option Scheme adopted by HU
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 14 Dec 2021

HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, December 14, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces new analyses on the ongoing studies of HMPL-523 presented at the 63rd American Society for
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 10 Dec 2021

HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting
Hong Kong, Shanghai & Florham Park, NJ — Friday, December 10, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of surufatinib combined with toripalima
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 6 Dec 2021

HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
— Recruitment of 687 patients globally completed in fifteen months, ahead of schedule — — FRESCO-2 primary objective is to confirm overall clinical benefit seen in the China FRESCO pivotal study[1], and to support global registrations —
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 3 Dec 2021

HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in China
Hong Kong, Shanghai & Florham Park, NJ –– Friday, December 3, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that, following the 2021 negotiations with the China National Healthcare Security Adminis
Read More
HKEX - INSIDE INFORMATION (PDF)LSE RNS Announcement (PDF)
1234
5
67891011121314151617